Clinical trials

8

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Apheresis Collection for New Drug Development and Evaluation Research

Peripheral Blood Mononuclear Cells (PBMC) are a mixed population of cells with a single nucleus found in peripheral blood (i.e., blood outside the bone marrow), including natural killer cells (NK), T lymphocytes (70% - 90%), and B lymphocytes. They can be further isolated and purified and are the main source of immune cells. This study will be conducted at our hospital, with a planned recruitment of 200 subjects. Subjects who meet the inclusion criteria and do not meet the exclusion criteria will have their peripheral blood mononuclear cells collected via apheresis. Each subject will need to provide an apheresis sample containing approximately 8×10\^9 mononuclear cells (with a sample volume of about 150 mL).

Participants needed: 200
Trial details
Age: 18-40Biological sex: AllType: ObservationalSponsor: TCRx Therapeutics Co.LtdUpdated: Jun 23, 2026Locations: 2
Eligibility criteria

Aged between 18 and 40 (inclusive), male or non-pregnant female, regardless of n...

Previously had adverse reactions to blood donation. The following diseases are c...

Status: Recruiting

KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: May 19, 2026Locations: 1
Eligibility criteria

Voluntarily participate in the clinical study; fully understand the study and vo... [+7]

A history of other malignant tumors within 2 years prior to signing the informed... [+35]

Status: Recruiting

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.

Participants needed: 18
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

Patients or their legal guardians voluntarily participate in the study and provi... [+9]

History of another primary malignancy that has not been in continuous remission... [+19]

Status: Not yet recruiting

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Dec 10, 2025Locations: 1
Eligibility criteria

Voluntarily participate in the clinical study; fully understand the study and vo... [+6]

A history of other malignant tumors within 2 years prior to signing the informed... [+50]

Status: Not yet recruiting

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Sep 29, 2025Locations: 1
Eligibility criteria

Voluntarily participate in the clinical study; fully understand the study and vo... [+6]

A history of other malignant tumors within 2 years prior to signing the informed... [+50]

Status: Recruiting

KSX01-TCRT Injection Project in Solid Tumors

1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Apr 13, 2023Locations: 1
Eligibility criteria

1) Voluntary participation in clinical research; Fully understand the study and... [+4]

6.1.1) Hemoglobin 90 g/L (no blood transfusion or erythropoietin treatment withi... [+64]

Status: Recruiting

KSH01-TCRT Solid Tumors

1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Apr 3, 2023Locations: 1
Eligibility criteria

Voluntarily participate in clinical research; fully understand this research and... [+6]

The neutrophil count (ANC) is not lower than the lower limit of the normal value... [+52]

Status: Recruiting

KSH01-R02-101 Solid Tumors

1. . safety and tolerance 2. . objective response rate

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: TCRx Therapeutics Co.LtdUpdated: Apr 3, 2023Locations: 1
Eligibility criteria

1) Voluntary participation in clinical research; Fully understand the study and... [+4]

6.1.1) Neutrophil count (ANC) is not lower than the lower limit of normal value... [+53]